BACTHECAL baclofen 10 mg/5 mL intrathecal solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

bacthecal baclofen 10 mg/5 ml intrathecal solution for injection ampoule

medsurge pharma pty ltd - baclofen, quantity: 10 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - baclofen solution for intrathecal injection is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

BACTHECAL baclofen 10 mg/20 mL intrathecal solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

bacthecal baclofen 10 mg/20 ml intrathecal solution for injection ampoule

medsurge pharma pty ltd - baclofen, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; sodium chloride - baclofen solution for intrathecal injection is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

BACTHECAL baclofen 0.05 mg/1 mL intrathecal solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

bacthecal baclofen 0.05 mg/1 ml intrathecal solution for injection ampoule

medsurge pharma pty ltd - baclofen, quantity: 0.05 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - baclofen solution for intrathecal injection is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

STELARA ustekinumab 90 mg/1 mL solution for injection pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

stelara ustekinumab 90 mg/1 ml solution for injection pre-filled syringe

janssen-cilag pty ltd - ustekinumab, quantity: 90 mg - injection, solution - excipient ingredients: histidine hydrochloride monohydrate; sucrose; water for injections; polysorbate 80; histidine - plaque psoriasis,adults - stelara is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.,paediatric population, 6 years and older - stelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from 6 years of age who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,psoriatic arthritis (psa),stelara, alone or in combination with methotrexate, is indicated for the treatment of signs and symptoms of active psoriatic arthritis in adult patients (18 years and older) where response to previous non-biological dmard therapy has been inadequate.,crohn?s disease,stelara is indicated for the treatment of adult patients with moderately to severely active crohn?s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a tnf alpha antagonist or have medical contraindications to such therapies.,ulcerative colitis,stelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

STELARA ustekinumab 45 mg/0.5 mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

stelara ustekinumab 45 mg/0.5 ml solution for injection vial

janssen-cilag pty ltd - ustekinumab, quantity: 45 mg - injection, solution - excipient ingredients: histidine; polysorbate 80; histidine hydrochloride monohydrate; water for injections; sucrose - plaque psoriasis,adults - stelara is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.,paediatric population, 6 years and older - stelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from 6 years of age who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,psoriatic arthritis (psa),stelara, alone or in combination with methotrexate, is indicated for the treatment of signs and symptoms of active psoriatic arthritis in adult patients (18 years and older) where response to previous non-biological dmard therapy has been inadequate.,crohn?s disease,stelara is indicated for the treatment of adult patients with moderately to severely active crohn?s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a tnf alpha antagonist or have medical contraindications to such therapies.,ulcerative colitis,stelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

KEPPRA levetiracetam 100 mg/mL oral solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

keppra levetiracetam 100 mg/ml oral solution bottle

ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: acesulfame potassium; purified water; maltitol solution; methyl hydroxybenzoate; ammonium glycyrrhizinate; citric acid monohydrate; propyl hydroxybenzoate; sodium citrate dihydrate; glycerol; flavour - keppra (film coated tablets and oral solution) is indicated for - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation, - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. - add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and - add on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige). keppra concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Dexamethasone (base) 3.3mg/1ml solution for injection ampoules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dexamethasone (base) 3.3mg/1ml solution for injection ampoules

base) 3.3mg/1ml solution for injection ampoules (wockhardt uk ltd - dexamethasone sodium phosphate - solution for injection - 3.3mg/1ml

PLERIXAFOR ARX plerixafor 24 mg/1.2 mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

plerixafor arx plerixafor 24 mg/1.2 ml solution for injection vial

arrotex pharmaceuticals pty ltd - plerixafor, quantity: 24 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - plerixafor arx is indicated in combination with granulocyte-colony stimulating factor (g-csf) to mobilise haematopoietic stem cells (hscs) to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma (mm).

TOBI SOLUTION FOR INHALATION Israel - English - Ministry of Health

tobi solution for inhalation

dexcel ltd, israel - tobramycin - solution for inhalation - tobramycin 300 mg / 5 ml - tobramycin - tobramycin - tobi is indicated for the management of pulmonary pseudomonas aeruginosa infection in cystic fibrosis (cf) patients age 6 years or older.

SPORANOX ORAL SOLUTION Israel - English - Ministry of Health

sporanox oral solution

j-c health care ltd - itraconazole - solution - itraconazole 10 mg/ml - itraconazole - itraconazole - sporanox oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. prevention of fungal infection during neutropenia of immunodeficient patients.